Roche and UK-based Chugai Pharmaceutical have reported positive data from the Phase III HAVEN 1 clinical trial of emicizumab in patients suffering from haemophilia A.
Emicizumab is a bispecific monoclonal antibody being developed to combine IXa and X factors that are needed for natural coagulation cascade activation and restoration of blood clotting.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Created by Chugai, the investigational candidate is being co-developed by the firm with Roche and Genentech.
The HAVEN 1 trial met the primary endpoint with a clinically meaningful and statistically significant decrease of 87% in bleed rate compared to on-demand bypassing agents (BPAs).
The randomised, multi-centre, open-label HAVEN 1 trial evaluated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous emicizumab prophylaxis in 109 adult and adolescent subjects.
Based on the results, it was found that all the 12 secondary endpoints of the trial were positive with a 79% reduced bleed rate during an intra-patient analysis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFollowing a median observation time of 31 weeks, results further showed no bleeds with emicizumab in a larger proportion of patients.
Roche head of global product development and chief medical officer Sandra Horning said: “Based on the bleed reduction shown in the HAVEN 1 and HAVEN 2 studies, we believe emicizumab has the potential to make a meaningful difference for people with haemophilia A with inhibitors, while also reducing the burden of managing the condition with a subcutaneous, once-weekly administration.”
In addition, the firms reported the Phase III HAVEN 2 trial’s interim results were found to be consistent with the results from HAVEN 1.
HAVEN 2 evaluated the efficacy, safety, and pharmacokinetics of emicizumab in 19 patients under 12 years old.
During the single-arm, multi-centre, open-label trial, an intra-patient comparison revealed a 100% decrease in treated bleeds with once-weekly subcutaneous emicizumab.
Roche has submitted both HAVEN 1 and HAVEN 2 findings to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for approval.
